US-based DOR BioPharma has entered into an agreement with Korean pharma company BL&H. As part of the deal, BL&H will act as DOR's sponsor of a Named Patient Program (NPP) for orBec to patients suffering from acute gastrointestinal Graft-versus-Host disease (GI GVHD) in South Korea.
DOR BioPharma, is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents.
BL&H specializes in hospital-based products in hematology, oncology, rheumatology and respiratory medicines.
BL&H and DOR will share revenues generated by sales of orBec through the NPP. DOR will manufacture and supply orBec to BL&H, while BL&H will be responsible for all distribution costs in South Korea.
The NPP is a compassionate use drug supply program administered by the Korea Orphan Drug Center (KODC) under which medical practitioners can legally supply investigational drugs to their patients who qualify. Under this program, investigational drugs can be administered through KODC to patients who are suffering from serious illnesses until the Korea Food & Drug Administration approves the drug.